Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Abstract EN

Multiple myeloma occurs primarily in elderly patients.

Considering the high prevalence of comorbidities, comorbidity is an important issue for the management of myeloma.

However, the impact of comorbidity on clinical outcomes has not been fully investigated.

We retrospectively analyzed patients with newly diagnosed myeloma.

Comorbidities were assessed based on the Charlson comorbidity index (CCI) and the Freiburg comorbidity index (FCI).

The CCI is a summary measure of 19 comorbid conditions.

FCI is determined by performance status, renal impairment, and lung disease.

This study included 127 patients with a median age of 71 years.

Approximately half of the patients had additional disorders at the time of diagnosis, and diabetes mellitus was the most frequent diagnosis (18.9%).

The most significant factors for prognosis among patient-related conditions were a history of solid cancer and performance status (ECOG ≥ 2).

The FCI score was divided into 3 groups (0, 1, and 2-3), and the CCI score was divided into 2 groups (2-3 and ≥4).

FCI was a strong prognostic tool for OS (P>0.001) and predicted clinical outcome better than CCI (P=0.059).

In conclusion, FCI was more useful than CCI in predicting overall survival in elderly patients with myeloma.